A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma Meeting Abstract
| Authors: | Shah, M. A.; Ilson, D.; Ramanathan, R. K.; Levner, A.; D'adamo, D.; Schwartz, L.; Casper, E.; Schwartz, G. K.; Kelsen, D. P. |
| Abstract Title: | A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma |
| Meeting Title: | 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 23 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2005 May 13-17 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2005-06-01 |
| Start Page: | 314S |
| Language: | English |
| ACCESSION: | WOS:000230326602075 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2005.23.16_suppl.4025 |
| Notes: | --- - Meeting Abstract: 4025 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
